Novo Nordisk and Hims appear to have buried the hatchet. Hims & Hers is going to sell the name-brand Novo weight loss drugs on its website at a discount, and says it’s going to limit compounding. Novo moved to drop its lawsuit against Hims. Regulators seem happy. But who came out ahead in the deal?
The Endpoints News health tech team (+ friends!) is taking over Post-Hoc Live today at 11:30 a.m. ET to break down where the balance falls. I’ll be joined by Endpoints health tech correspondent Shelby Livingston, who’s covered the Hims saga extensively, and Endpoints Novo expert and senior biopharma journalist Elizabeth Cairns.
We’ll be live on YouTube here, and you can set a calendar reminder for showtime.
I’m excited to talk about the winners and losers in this whole saga, what it means for the compounding and weight loss drug ecosystems more broadly, and if we think the less-compounding promise from Hims is actually going to stick.
See you soon!
— Lydia Ramsey Pflanzer